Table 4 Comparison of the current study with other pediatric HL studies conducted in low-middle-income countries
Author | Country | Protocol | Radiotherapy | EFS (%) | OS (%) |
|---|---|---|---|---|---|
Present study | Egypt | ABVD | No Rth for RES | 90 | 95 |
15 Gy for SER | 74.1 | 88.9 | |||
Tariq Ghafoor et al. (2018) [27] | Pakistan | OEPA/COPDAC | 19.8 Gy | 82.4 | 91.2 |
10 Gy boost | |||||
Faizan et al. (2016) [8] | Pakistan | OEPA/COPDAC | 19.8 Gy | 84 | 92 |
10 Gy boost | |||||
Fadoo et al. (2010) [15] | Pakistan | COPP/ABVD | Does not mentioned | 94 | 94 |
Faizan et al. (2016) [8] | UK | OEPA/COPDAC | 19.8 Gy | 92 | 100 |
10 Gy boost | |||||
Arya et al. (2006) [16] | India | COPP/ABVD | 20–25 Gy | 87.9 | 91.5 |
Trehan et al. (2013) [5] | India | MOPP, COPP, and ABVD | Dose not mentioned | 77.7 | 92.7 |
Bhethanabhotla et al. (2017) [10] | India | ABVD | 25 Gy to bulky site | 84.8 | 95.3 |
Sherief et al. (2015) [11] | Egypt | ABVD | 21–35 Gy | 84.7 | 96.6 |
Geel et al. (2017) [28] | South Africa | COPP/ABVD | 14–44 Gy | 79 | |
OEPA/OPPA | |||||
CHIVPP | |||||
Castellanos et al. (2014) [6] | Central America | ABV/COPP | No | 71 | |
Zubizarreta et al. (2017) [29] | Argentina | ABVD | 25 Gy | 84 | 95 |
Samy Elbadawy et al. (2008) [30] | Egypt | OPPA, E-OPA/ COPP | 20–30 Gy | 86.1 | 95.3 |
Amany M. Ali et al. 2018 [24] | Egypt | ABVD/COEP | 15 Gy for CR | 71.8 | 81.8 |
25.5 Gy for PR |